BISPECIFIC T-CELL ENGAGING ANTIBODIES FOR CANCER THERAPY

• In: A7 - Cancer immunotherapy: using drugs and cells to exploit our immune systems on Friday, 2 October 2015, 09:00-12:00
• At: Düsseldorf (Germany) (2015)
• Type: Presentation
• By: WOLF, Andreas (Amgen Research Munich, München, Germany)
• Co-author(s): Andreas Wolf
  
• Abstract:

  BiTE™ antibodies are single-chain bispecific antibody constructs with specificity for CD3 on T cells and a selected surface antigen on target cells. By transiently bridging T cells and cancer cells, BiTE™ antibodies are capable to fully activate T cells and to mount a polyclonal T cell response that is no longer restricted by T cell receptor

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login